Podiatrists in Port Arthur, TX Accepting Medicare

4 Podiatrists found. Showing 1 - 4

Mid-county Foot Specialist Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 7980 Anchor Dr, Building 200, Port Arthur, TX 77642 Phone: 409-722-4141    Fax: 409-722-2788

Richard A Schleiffer Dpm Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 3626 Professional Dr, Port Arthur, TX 77642 Phone: 409-983-6779    Fax: 409-983-6102

Michael C Percenti, Dpm Pllc Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 7980 Anchor Dr, Ste # 700b, Port Arthur, TX 77642 Phone: 409-722-4141    Fax: 409-722-2788

Dr. Richard G Bowling, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2501 Jimmy Johnson Blvd, #400, Port Arthur, TX 77640 Phone: 409-729-5633    Fax: 409-729-9760

News Archive

USF Health, FORCE receive $1.45 million from PCORI to advance and expand clinical research network

A team led by the University of South Florida Morsani College of Medicine and the leading national hereditary breast and ovarian cancer advocacy organization, FORCE (Facing Our Risk of Cancer Empowered) received a $1.45-million funding award for a three-year project from the Patient-Centered Outcomes Research Institute to continue to advance and expand the ABOUT Network as part of the second phase of PCORnet: the National Patient-Centered Clinical Research Network.

Consumer Reports launches web-based tool that offers personalized guidance on health insurance

Consumer Reports, the nonprofit consumer service organization empowering consumers for more than 75 years, today announced the launch of HealthLawHelper.org, an innovative web-based tool that offers personalized guidance to help consumers better understand how they may be affected by the Affordable Care Act.

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering its novel Toll-like Receptor (TLR) - targeted compounds. The Company's TLR-targeted compounds are based on synthetic DNA and RNA, which it refers to as immune modulatory oligonucleotides, or IMO®.

Microchip-based device determines the genetic signature of lung tumors

Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.

Read more Medical News

› Verified 6 days ago